News
Displaying 11–20 of 525
-
Research News
In this in-depth interview hosted by InVivo, Jason Menzo, CEO of the Foundation Fighting Blindness, outlines the organization’s strategy for addressing significant changes and opportunities in the inherited retinal diseases (IRDs).
-
In the Press
Opus Genetics secures up to $2M in non-dilutive funding from the RD Fund to advance its OPGx-MERTK gene therapy program targeting retinitis pigmentosa caused by MERTK mutations.
-
José-Alain Sahel Awarded 2026 ARVO Proctor Medal for Groundbreaking Research Achievements
Research NewsDr. Sahel’s research has led to several emerging retinal disease therapies that have moved into clinical trials.
-
Foundation News
Jason Menzo Urges Robust FY2026 Funding for National Eye Institute and Protection of Its Independent Status.
-
Foundation News
Chairwoman Capito, Ranking Member Baldwin, and members of the Senate Appropriations Labor, Health and Human Services, Education, and Related Agencies Subcommittee, the Foundation Fighting Blindness appreciates the opportunity to provide written testimony to the subcommittee as an outside witness.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
Presentation Summaries from the 10th Annual Retinal Therapy Innovation Summit
Research NewsIn its tenth year, the Innovation Summit featured 28 presentations from industry professionals worldwide and more than 400 attendees.
-
ARVO 2025 Highlight: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Research NewsDespite missing the primary endpoint, the treatment improved vision for some patients.
-
Research News
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.
